| 產品編號 | bs-4846R-BF350 |
| 英文名稱 | Rabbit Anti-Factor VII heavy chain/BF350 Conjugated antibody |
| 中文名稱 | BF350標記的凝血因子7抗體 |
| 別 名 | Factor VII heavy chain; coagulation factor VII (serum prothrombin conversion accelerator); Coagulation factor VII; Eptacog alfa; F7; FA7_HUMAN; Factor VII; Factor VII light chain; FVII coagulation protein; OTTHUMP00000018733; OTTHUMP00000018734; Proconvertin; Serum prothrombin conversion accelerator; SPCA. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 心血管 細胞生物 免疫學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, ) |
| 產品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 17/28kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Factor VII heavy chain |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. Function: Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. Subunit: Heterodimer of a light chain and a heavy chain linked by a disulfide bond. Subcellular Location: Secreted. Tissue Specificity: Plasma. Post-translational modifications: The vitamin K-dependent, enzymatic carboxylation of some glutamate residues allows the modified protein to bind calcium. The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. DISEASE: Defects in F7 are the cause of factor VII deficiency (FA7D) [MIM:227500]. A hemorrhagic disease with variable presentation. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or repeated hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Finally, numerous subjects are completely asymptomatic despite very low factor VII levels. Similarity: Belongs to the peptidase S1 family. Contains 2 EGF-like domains. Contains 1 Gla (gamma-carboxy-glutamate) domain. Contains 1 peptidase S1 domain. Database links: Entrez Gene: 2155 Human Omim: 613878 Human SwissProt: P08709 Human Unigene: 36989 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 凝血因子7是肝臟合成的一種維生素K依賴性的單鏈糖蛋白,由4 0 6個氨基酸殘基組成,分子量約45kD。 凝血因子Ⅶ的半衰期最短（4～6h），血漿含量較低（0.5～2mg/L），故可作為肝病患者蛋白質合成功能減退的早期診斷指標。在慢性肝病患者通過肝活檢組織原位雜交的方法檢測到凝血因子Ⅶ的表達與肝纖維化的分級呈負相關，可作為預測纖維化程度的指標。凝血因子Ⅶ活性還與預后有著密切的聯(lián)系，經研究認為：凝血因子Ⅶ活性<34%的肝硬化患者93%在隨訪10月內死亡，故認為它是肝硬化患者預后好壞的早期預測指標，可更好識別肝移植候選人。肝硬化患者凝血因子Ⅶ活性可明顯下降，凝血因子Ⅶ缺乏可導致血小板活性的改變，結合血小板計數(shù)減少使出血時間延長，因此對有創(chuàng)診斷與治療的肝硬化患者，還應該用凝血因子Ⅶ活性進行出血危險度的評估，而不能僅看血小板計數(shù)。除診斷之外，重組凝血因子Ⅶ可以有效地糾正肝病患者凝血異常，有利于有創(chuàng)性檢查的進行。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
